2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Immunology, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5338 Improved safety and tolerability of glofitamab monotherapy in relapsed/refractory mantle cell lymphoma using enhanced cytokine release syndrome mitigation measures: An extension cohort from the Phase II NP30179 study

Yasmin H Karimi, MD, Tycel Phillips, MD, FASCO2, Michael Dickinson, MBBS (Hons), DMedSci FRACP, FRCPA3, Franck Morschhauser, phd4, Carmelo Carlo-Stella, MD5, Fritz Offner, MD, PhD6, Emmanuel Bachy I, MD, PhD7, Nancy L. Bartlett, MD8, Joshua D. Brody, MD9, Jan M. Zaucha Sr, MD, PhD10, Tomasz Wrobel, MD, PhD11, Raluca Negricea12, James Relf13, Wilfred Leung, PhD, DVM14, Ben Byrne15, Martine Kallemeijn16, Aurelien Berthier, MD17, Gila Sellam, PhD18, Linda Lundberg, PhD19, Martin Hutchings20
1 Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 Peter MacCallum Cancer Centre, Melbourne, Australia
4 Centre Hospitalier Universitaire de Lille, Lille, France
5 Humanitas University and IRCCS Humanitas Research Hospital, Milano, Italy
6 Dept Hematology Universitair Ziekenhuis, Gent, Belgium
7 Hospices Civils de Lyon and Université Claude Bernard, Pierre-Bénite, France
8 Siteman Cancer Center, St. Louis, Missouri, United States
9 Tisch Cancer Institute, New York, New York, United States
10 Medical University of Gdansk and University Clinical Center, Gdansk, Poland
11 Wroclaw Medical University, Wroclaw, Poland
12 Roche Products Ltd, Welwyn Garden City, United Kingdom
13 Roche Products Ltd, Welwyn Garden City, United Kingdom
14 Genentech, Inc., South San Francisco, California, United States
15 Roche Products Ltd, Welwyn Garden City, United Kingdom
16 F. Hoffmann-La Roche Ltd, Basel, Switzerland
17 F. Hoffmann-La Roche Ltd, Basel, Switzerland
18 F. Hoffmann-La Roche Ltd, Basel, Switzerland
19 F. Hoffmann-La Roche Ltd, Basel, Switzerland
20 Rigshospitalet and University of Copenhagen, Copenhagen, Denmark

Background: In the prior analysis of the initial relapsed/refractory (R/R) mantle cell lymphoma (MCL) cohort (N=60) of the Phase I/II NP30179 (NCT03075696) study, glofitamab monotherapy achieved high and durable responses (overall response rate, 82%; complete response [CR], 77%; median duration of CR, 40.8 months), with a manageable safety profile, regardless of prior Bruton’s tyrosine kinase inhibitor exposure (Karimi et al. ASCO 2026). During the study, experience with cytokine release syndrome (CRS) management led to the implementation of an enhanced mitigation strategy designed to improve safety and tolerability. We report the impact of the enhanced CRS mitigation strategy on safety outcomes in patients with R/R MCL, alongside safety data from the initial R/R MCL cohort.

Methods: Patients in the initial R/R MCL cohort received standard CRS mitigation: obinutuzumab pretreatment with a single dose of intravenous (IV) dexamethasone (Dex; 20mg) prior to glofitamab infusion. Patients in the enhanced CRS mitigation cohort received additional steroid premedication with oral Dex (20mg) on the days before and after glofitamab step-up-dose (SUD) infusions (Day [D]8, 2.5mg; D15, 10mg). Additional measures implemented in the enhanced CRS mitigation cohort were prolonged SUD infusion time (from 4 to 8 hours); early tocilizumab administration for grade (Gr) 1 CRS events; modified glofitamab interruption/re-initiation guidance (stop infusion if CRS occurs; do not restart after CRS resolution); and additional Dex administration with the first target dose of glofitamab (30mg), if Gr ≥2 CRS was reported during glofitamab SUD. CRS was graded by American Society for Transplantation and Cellular Therapy criteria (ASTCT).

Results: In the initial cohort (N=60), median survival follow-up was 41.5 months; median number of treatment cycles was 12. In the enhanced CRS mitigation cohort (N=20), median survival follow-up was 4.9 months; median number of treatment cycles was eight. The incidence of CRS was numerically lower, with a lower severity in the enhanced CRS mitigation cohort than in the initial cohort. The rate of any grade CRS in the enhanced CRS mitigation cohort was 50.0% (n=10/20; Gr 1, 25.0% [n=5]; Gr 2, 15.0% [n=3]; Gr 3, 10.0% [n=2]; Gr 4, 0%; Gr 5, 0%); events were limited to the first 2.5mg glofitamab dose. The rate of any grade CRS in the initial cohort was 70.0% (n=42/60; Gr 1, 36.7% [n=22]; Gr 2, 21.7% [n=13]; Gr 3, 8.3% [n=5]; Gr 4, 3.3% [n=2]; Gr 5, 0%); events mainly occurred during SUD. Serious CRS events occurred in 25.0% (n=5) and 36.7% (n=22) of patients in the enhanced CRS mitigation cohort and initial cohort, respectively. Consistent with updated CRS management guidance, use of Dex (70.0% vs 38.1%) and tocilizumab (90.0% vs 50.0%) for CRS management were higher in the enhanced CRS mitigation cohort than in the initial cohort. Immune effector cell-associated neurotoxicity syndrome (ICANS; Gr 1) was reported in one patient in the enhanced CRS mitigation cohort; in the initial cohort, neurologic adverse events (AEs) potentially consistent with ICANS were reported in 11.7% of patients (n=7; Gr 1, 6.7% [n=4]; Gr 2, 5.0% [n=3]). A numerically lower rate of infections was observed in the enhanced CRS mitigation cohort (Gr 3, 10.0% [n=2]; Gr 4, 0%; Gr 5, 0%) than in the initial cohort (Gr 3, 20.0% [n=12]; Gr 4, 1.7% [n=1]; Gr 5, 13.3% [n=8]). Fewer serious AEs (45.0% vs 78.3%) and discontinuations due to AEs (5.0% vs 8.3%) were reported in the enhanced CRS mitigation cohort than the initial cohort. No fatal events occurred in the enhanced CRS mitigation cohort; in the initial cohort, Gr 5 events occurred in 15.0% of patients (n=9; six COVID-19-related events). However, these differences should be interpreted in the context of a shorter follow-up time (median, 4.9 vs 41.5 months) and lower glofitamab exposure in the enhanced CRS mitigation cohort compared with the initial cohort, as well as fewer COVID-19 events due to the different enrollment periods. Detailed baseline and disease characteristics, and CRS, infection, and biomarker data will be presented.

Conclusion: These data suggest that an enhanced CRS mitigation strategy improved overall safety and tolerability of fixed-duration glofitamab monotherapy in patients with R/R MCL. Additional Dex premedication and early intervention effectively minimized the overall incidence and severity of CRS.

Yasmin H Karimi, MD: Roche-Genentech - Honoraria; AbbVie - Research Funding; Loxo-Lilly - Research Funding; Kite Pharma - Research Funding; Immunome - Research Funding; Pfizer - Research Funding; Merck - Research Funding; Genmab - Research Funding; AstraZeneca - Research Funding; Roche-Genentech - Research Funding; BeiGene - Research Funding; Foresight Diagnostics - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Roche-Genentech - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)